|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.88 USD | -0.71% |
|
-7.67% | +31.52% |
| Capitalization | 7.39B 6.37B 5.98B 5.55B 10.24B 667B 11.17B 69.63B 26.96B 315B 27.75B 27.16B 1,153B | P/E ratio 2025 * |
11.6x | P/E ratio 2026 * | 8.51x |
|---|---|---|---|---|---|
| Enterprise value | 8.12B 6.99B 6.56B 6.1B 11.24B 732B 12.26B 76.44B 29.6B 346B 30.47B 29.81B 1,266B | EV / Sales 2025 * |
6.05x | EV / Sales 2026 * | 4.25x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | -0.71% | ||
| 1 week | -7.67% | ||
| Current month | -11.93% | ||
| 1 month | -7.85% | ||
| 3 months | -17.10% | ||
| 6 months | +15.91% | ||
| Current year | +31.52% |
| 1 week | 61.7 |  | 67.1 |
| 1 month | 61.7 | | 74.25 |
| Current year | 47.5 | | 79.5 |
| 1 year | 46.26 | | 79.5 |
| 3 years | 29.85 | | 79.5 |
| 5 years | 29.85 | | 79.5 |
| 10 years | 6.96 | | 79.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 62 | 2014-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 42 | 2022-02-01 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 61 | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 57 | 2013-03-27 |
Helen Torley
BRD | Director/Board Member | 62 | 2014-01-05 |
| Chairman | 60 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | -7.67% | +29.92% | +8.69% | 7.39B | |
| -1.32% | +2.23% | -14.67% | -31.92% | 60.16B | |
| -0.40% | -4.45% | +0.08% | -18.64% | 8.46B | |
| -0.52% | -3.34% | +30.94% | +86.43% | 7.11B | |
| -1.02% | -4.76% | +1.04% | +114.41% | 5.9B | |
| +4.21% | +8.93% | +222.47% | +74.20% | 4.57B | |
| +1.24% | -1.87% | -16.10% | -4.42% | 2.87B | |
| +3.24% | +5.50% | +26.88% | +32.55% | 2.7B | |
| +0.16% | +0.56% | +20.58% | +40.69% | 2.55B | |
| -0.48% | -0.39% | -16.29% | +4.90% | 1.95B | |
| Average | +0.53% | +0.30% | +28.49% | +30.69% | 10.37B | |
| Weighted average by Cap. | -0.13% | +0.75% | +6.07% | -1.89% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.34B 1.16B 1.08B 1.01B 1.86B 121B 2.03B 12.64B 4.89B 57.14B 5.04B 4.93B 209B | 1.68B 1.44B 1.35B 1.26B 2.32B 151B 2.53B 15.78B 6.11B 71.34B 6.29B 6.16B 261B |
| Net income | 667M 574M 539M 501M 924M 60.13B 1.01B 6.28B 2.43B 28.39B 2.5B 2.45B 104B | 890M 766M 720M 669M 1.23B 80.28B 1.35B 8.38B 3.25B 37.9B 3.34B 3.27B 139B |
| Net Debt | 723M 622M 584M 543M 1B 65.16B 1.09B 6.81B 2.64B 30.77B 2.71B 2.65B 113B | -273M -235M -221M -205M -378M -24.64B -413M -2.57B -996M -11.63B -1.03B -1B -42.61B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-08 | 62.88 $ | -0.71% | 1,903,438 |
| 25-12-05 | 63.33 $ | +0.60% | 1,550,678 |
| 25-12-04 | 62.95 $ | -2.64% | 4,213,503 |
| 25-12-03 | 64.66 $ | -2.83% | 2,863,540 |
| 25-12-02 | 66.54 $ | -2.29% | 1,865,892 |
Delayed Quote Nasdaq, December 08, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition